StockNews.com Downgrades Prestige Consumer Healthcare (NYSE:PBH) to Hold

StockNews.com lowered shares of Prestige Consumer Healthcare (NYSE:PBH) from a buy rating to a hold rating in a research report sent to investors on Monday.

Several other analysts have also recently commented on the company. Canaccord Genuity Group raised their target price on Prestige Consumer Healthcare from $93.00 to $100.00 and gave the company a “buy” rating in a research report on Friday, February 7th. DA Davidson raised their price target on Prestige Consumer Healthcare from $95.00 to $104.00 and gave the company a “buy” rating in a report on Friday, February 7th. Sidoti downgraded shares of Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Raymond James raised shares of Prestige Consumer Healthcare to a “moderate buy” rating in a research note on Thursday, December 19th. Finally, Oppenheimer upped their price target on shares of Prestige Consumer Healthcare from $87.00 to $93.00 and gave the stock an “outperform” rating in a research note on Thursday, February 13th. Three equities research analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, Prestige Consumer Healthcare currently has a consensus rating of “Moderate Buy” and an average price target of $92.60.

Prestige Consumer Healthcare Stock Performance

Shares of PBH opened at $82.83 on Monday. The firm has a fifty day moving average of $81.22 and a 200-day moving average of $78.12. The company has a market cap of $4.10 billion, a price-to-earnings ratio of 19.40, a price-to-earnings-growth ratio of 2.69 and a beta of 0.46. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.20 and a current ratio of 3.68. Prestige Consumer Healthcare has a 1 year low of $62.35 and a 1 year high of $90.04.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, February 6th. The company reported $1.22 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.18 by $0.04. Prestige Consumer Healthcare had a net margin of 19.13% and a return on equity of 12.36%. As a group, equities analysts anticipate that Prestige Consumer Healthcare will post 4.5 earnings per share for the current year.

Insider Buying and Selling at Prestige Consumer Healthcare

In related news, SVP Mary Beth Fritz sold 1,678 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The shares were sold at an average price of $90.00, for a total value of $151,020.00. Following the sale, the senior vice president now directly owns 17,157 shares in the company, valued at $1,544,130. The trade was a 8.91 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 1.60% of the stock is owned by corporate insiders.

Institutional Trading of Prestige Consumer Healthcare

Large investors have recently added to or reduced their stakes in the business. Universal Beteiligungs und Servicegesellschaft mbH bought a new position in shares of Prestige Consumer Healthcare in the fourth quarter valued at $7,778,000. Kayne Anderson Rudnick Investment Management LLC acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $84,932,000. Vise Technologies Inc. acquired a new stake in shares of Prestige Consumer Healthcare during the fourth quarter worth $319,000. McIlrath & Eck LLC lifted its holdings in shares of Prestige Consumer Healthcare by 19.1% during the fourth quarter. McIlrath & Eck LLC now owns 959 shares of the company’s stock valued at $75,000 after purchasing an additional 154 shares during the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Prestige Consumer Healthcare by 24.6% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 118,113 shares of the company’s stock valued at $9,223,000 after purchasing an additional 23,334 shares during the period. 99.95% of the stock is currently owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.